Incyte Revenue 2006-2019 | INCY

Incyte annual/quarterly revenue history and growth rate from 2006 to 2019. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
  • Incyte revenue for the quarter ending September 30, 2019 was $0.552B, a 22.66% increase year-over-year.
  • Incyte revenue for the twelve months ending September 30, 2019 was $2.108B, a 17.25% increase year-over-year.
  • Incyte annual revenue for 2018 was $1.882B, a 22.5% increase from 2017.
  • Incyte annual revenue for 2017 was $1.536B, a 38.93% increase from 2016.
  • Incyte annual revenue for 2016 was $1.106B, a 46.7% increase from 2015.
Incyte Annual Revenue
(Millions of US $)
2018 $1,882
2017 $1,536
2016 $1,106
2015 $754
2014 $511
2013 $355
2012 $297
2011 $94
2010 $170
2009 $9
2008 $4
2007 $34
2006 $28
2005 $8
Incyte Quarterly Revenue
(Millions of US $)
Q3 2019 $552
Q2 2019 $530
Q1 2019 $498
Q4 2018 $528
Q3 2018 $450
Q2 2018 $522
Q1 2018 $382
Q4 2017 $444
Q3 2017 $382
Q2 2017 $326
Q1 2017 $384
Q4 2016 $326
Q3 2016 $269
Q2 2016 $246
Q1 2016 $263
Q4 2015 $244
Q3 2015 $188
Q2 2015 $163
Q1 2015 $159
Q4 2014 $124
Q3 2014 $198
Q2 2014 $100
Q1 2014 $90
Q4 2013 $97
Q3 2013 $85
Q2 2013 $102
Q1 2013 $71
Q4 2012 $114
Q3 2012 $60
Q2 2012 $87
Q1 2012 $36
Q4 2011 $29
Q3 2011 $17
Q2 2011 $17
Q1 2011 $32
Q4 2010 $86
Q3 2010 $17
Q2 2010 $50
Q1 2010 $17
Q4 2009 $7
Q3 2009 $1
Q2 2009 $1
Q1 2009 $1
Q4 2008 $1
Q3 2008 $1
Q2 2008 $1
Q1 2008 $1
Q4 2007 $10
Q3 2007 $7
Q2 2007 $11
Q1 2007 $7
Q4 2006 $7
Q3 2006 $7
Q2 2006 $7
Q1 2006 $6
Q4 2005 $1
Q3 2005 $1
Q2 2005 $3
Q1 2005 $3
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $17.339B $1.882B
Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company focused on the discovery, development, and commercialization of proprietary therapeutics. Their first commercial product, Jakafi (ruxolitinib), is approved in the United States for patients with intermediate or high-risk myelofibrosis and for patients with polycythemia vera who have had an inadequate response to or are intolerant of hydroxyurea. They have a diverse and growing portfolio of product candidates, including both small and large molecules.
Stock Name Country Market Cap PE Ratio
Amgen (AMGN) United States $143.489B 16.53
CSL (CSLLY) Australia $94.378B 0.00
Gilead Sciences (GILD) United States $79.679B 9.87
Vertex Pharmaceuticals (VRTX) United States $60.644B 61.90
Biogen (BIIB) United States $51.516B 8.84
Illumina (ILMN) United States $47.734B 52.37
Regeneron Pharmaceuticals (REGN) United States $42.374B 18.56
Alexion Pharmaceuticals (ALXN) United States $25.066B 12.38
Seattle Genetics (SGEN) United States $18.681B 0.00
SINO PHARMACEUT (SBMFF) Hong Kong, SAR China $18.631B 0.00
BioMarin Pharmaceutical (BMRN) United States $15.856B 0.00
Genmab (GNMSF) Denmark $13.895B 61.37
Alnylam Pharmaceuticals (ALNY) United States $13.247B 0.00
Galapagos (GLPG) Belgium $12.482B 32.16
Exact Sciences (EXAS) United States $11.433B 0.00
Bio-Rad Laboratories (BIO.B) United States $11.238B 53.94
BeiGene (BGNE) Cayman Islands $10.404B 0.00
Sarepta Therapeutics (SRPT) United States $9.534B 0.00
Bio-Techne Corp (TECH) United States $8.408B 56.28
QIAGEN (QGEN) Netherlands $8.064B 26.29
Guardant Health (GH) United States $7.944B 0.00
BioNTech SE (BNTX) Germany $7.507B 0.00
Horizon Therapeutics Public (HZNP) Ireland $7.192B 18.29
Amarin (AMRN) Ireland $7.112B 0.00
Moderna (MRNA) United States $6.872B 0.00
ACADIA Pharmaceuticals (ACAD) United States $6.689B 0.00
Reata Pharmaceuticals (RETA) United States $6.400B 0.00
Exelixis (EXEL) United States $6.022B 16.94
ARGENX SE-ADR (ARGX) Netherlands $5.884B 0.00
Ascendis Pharma (ASND) Denmark $5.862B 0.00
Bluebird Bio (BLUE) United States $5.425B 0.00
Repligen (RGEN) United States $5.243B 95.01
China Biologic Products (CBPO) China $4.558B 25.68
MorphoSys AG (MOR) Germany $4.166B 0.00
Blueprint Medicines (BPMC) United States $3.990B 0.00
Mirati Therapeutics (MRTX) United States $3.827B 0.00
Immunomedics (IMMU) United States $3.675B 0.00
Adaptive Biotechnologies (ADPT) United States $3.508B 0.00
Intercept Pharmaceuticals (ICPT) United States $3.473B 0.00
Ultragenyx Pharmaceutical (RARE) United States $3.464B 0.00
MyoKardia (MYOK) United States $3.409B 0.00
NeoGenomics (NEO) United States $3.346B 178.06
CRISPR Therapeutics AG (CRSP) Switzerland $3.220B 0.00
Zai Lab (ZLAB) China $3.085B 0.00
Alkermes (ALKS) Ireland $3.031B 0.00
Momenta Pharmaceuticals (MNTA) United States $3.030B 0.00
Acceleron Pharma (XLRN) United States $2.980B 0.00
UniQure (QURE) Netherlands $2.946B 0.00
Genmab (GMAB) Denmark $2.929B 6.03
Halozyme Therapeutics (HALO) United States $2.926B 0.00
Emergent Biosolutions (EBS) United States $2.868B 28.49
Amicus Therapeutics (FOLD) United States $2.653B 0.00
Epizyme (EPZM) United States $2.434B 0.00
Arena Pharmaceuticals (ARNA) United States $2.339B 5.44
RA PHARMCTL INC (RARX) United States $2.214B 0.00
Denali Therapeutics (DNLI) United States $2.147B 0.00
Myriad Genetics (MYGN) United States $2.136B 31.56
Principia Biopharma (PRNB) United States $2.070B 0.00
Fate Therapeutics (FATE) United States $1.939B 0.00
Zymeworks (ZYME) Canada $1.935B 0.00
Insmed (INSM) United States $1.917B 0.00
REGENXBIO (RGNX) United States $1.774B 0.00
Arvinas (ARVN) United States $1.718B 0.00
Akcea Therapeutics (AKCA) United States $1.601B 0.00
Ligand Pharmaceuticals (LGND) United States $1.588B 30.54
Editas Medicine (EDIT) United States $1.572B 0.00
Alector (ALEC) United States $1.474B 0.00
Dicerna Pharmaceuticals (DRNA) United States $1.461B 0.00
Intra-Cellular Therapies (ITCI) United States $1.455B 0.00
Nabriva Therapeutics AG (NBRV) Ireland $1.390B 0.00
Orchard Therapeutics (ORTX) United Kingdom $1.376B 0.00
Coherus BioSciences (CHRS) United States $1.344B 0.00
Zealand Pharma (ZLDPF) Denmark $1.292B 0.00
Athenex (ATNX) United States $1.184B 0.00
DBV Technologies S.A (DBVT) France $1.157B 0.00
Zealand Pharma (ZEAL) Denmark $1.156B 0.00
Codexis (CDXS) United States $1.060B 0.00
Revance Therapeutics (RVNC) United States $1.013B 0.00
Sangamo Therapeutics (SGMO) United States $0.970B 0.00
PHARMA MAR SA (PHMMF) Spain $0.965B 0.00
Pharming Group (PHGUF) Netherlands $0.939B 0.00
Mesoblast (MESO) Australia $0.936B 0.00
BAVARIAN NORDIC (BVNRY) Denmark $0.902B 0.00
Heska (HSKA) United States $0.845B 215.86
ZIOPHARM Oncology Inc (ZIOP) United States $0.840B 0.00
Vanda Pharmaceuticals (VNDA) United States $0.806B 6.78
Vericel (VCEL) United States $0.781B 291.17
Cellectis S.A (CLLS) France $0.774B 0.00
GENFIT S.A (GNFT) France $0.773B 0.00
Adverum Biotechnologies (ADVM) United States $0.757B 0.00
Twist Bioscience (TWST) United States $0.756B 0.00
ANI Pharmaceuticals (ANIP) United States $0.741B 12.63
NantKwest (NK) United States $0.723B 0.00
Cytokineticsorporated (CYTK) United States $0.717B 0.00
Intellia Therapeutics (NTLA) United States $0.715B 0.00
Sorrento Therapeutics (SRNE) United States $0.715B 0.00
Basilea Pharmaceutica AG (BPMUF) Switzerland $0.713B 0.00
UROGEN PHARMA (URGN) United States $0.707B 0.00
Retrophin (RTRX) United States $0.695B 0.00
Cara Therapeutics (CARA) United States $0.693B 0.00
Anika Therapeutics (ANIK) United States $0.648B 21.03
AC Immune SA (ACIU) Switzerland $0.622B 14.38
Kadmon Holdings (KDMN) United States $0.589B 0.00
OXFORD BIOMEDCL (OXBDF) United Kingdom $0.578B 0.00
Prothena (PRTA) Ireland $0.569B 0.00
Precision BioSciences (DTIL) United States $0.542B 0.00
Agenus (AGEN) United States $0.541B 0.00
Clovis Oncology (CLVS) United States $0.540B 0.00
BioDelivery Sciences (BDSI) United States $0.522B 0.00
Aquinox Pharmaceuticals (NLTX) United States $0.513B 0.00
Dynavax Technologies (DVAX) United States $0.506B 0.00
Autolus Therapeutics (AUTL) United Kingdom $0.504B 0.00
Bellus Health (BLU) Canada $0.486B 0.00
Adaptimmune Therapeutics (ADAP) United Kingdom $0.473B 0.00
Arcus Biosciences (RCUS) United States $0.469B 0.00
Sinovac Biotech (SVA) China $0.460B 0.00
Xenon Pharmaceuticals (XENE) Canada $0.450B 0.00
AnaptysBio (ANAB) United States $0.431B 0.00
Lexicon Pharmaceuticals (LXRX) United States $0.429B 2.97
Gritstone Oncology (GRTS) United States $0.402B 0.00
AMAG Pharmaceuticals (AMAG) United States $0.401B 0.00
Merus (MRUS) Netherlands $0.397B 0.00
Mersana Therapeutics (MRSN) United States $0.385B 0.00
Kindred Biosciences (KIN) United States $0.385B 0.00
Puma Biotechnology (PBYI) United States $0.379B 0.00
PDL BioPharma (PDLI) United States $0.372B 9.31
Avid Bioservices (CDMO) United States $0.368B 0.00
Syros Pharmaceuticals (SYRS) United States $0.361B 0.00
Cue Biopharma (CUE) United States $0.354B 0.00
Stemline Therapeutics (STML) United States $0.352B 0.00
POXEL SA FRANCE (PXXLF) France $0.350B 0.00
CytomX Therapeutics (CTMX) United States $0.339B 0.00
Cellular Biomedicine (CBMG) United States $0.337B 0.00
Inovio Pharmaceuticals (INO) United States $0.329B 0.00
Albireo Pharma (ALBO) United States $0.317B 0.00
Compugen (CGEN) Israel $0.314B 0.00
MannKind (MNKD) United States $0.312B 0.00
Starpharma Holdings (SPHRY) Australia $0.303B 0.00
OSMOTICA PHARM (OSMT) United States $0.302B 0.00
VBI Vaccines (VBIV) United States $0.291B 0.00
IVERIC Bio (ISEE) United States $0.282B 0.00
Geron (GERN) United States $0.282B 0.00
Sutro Biopharma (STRO) United States $0.276B 0.00
WAVE Life Sciences (WVE) Singapore $0.270B 0.00
ADMA Biologics Inc (ADMA) United States $0.265B 0.00
Kamada (KMDA) Israel $0.263B 7.67
ChromaDex (CDXC) United States $0.260B 0.00
Prometic Life Sciences (LMNL) Canada $0.257B 0.00
Biofrontera AG (BFRA) Germany $0.254B 0.00
Syndax Pharmaceuticals (SNDX) United States $0.245B 0.00
Seres Therapeutics (MCRB) United States $0.240B 0.00
Affimed (AFMD) Germany $0.230B 0.00
Aeglea BioTherapeutics (AGLE) United States $0.230B 0.00
Cerecor (CERC) United States $0.222B 0.00
Theratechnologies (THTX) Canada $0.218B 0.00
XOMA (XOMA) United States $0.215B 0.00
Exicure (XCUR) United States $0.214B 0.00
Nymox Pharmaceutical (NYMX) Canada $0.214B 0.00
Athersys (ATHX) United States $0.199B 0.00
Protagonist Therapeutics (PTGX) United States $0.199B 0.00
Bicycle Therapeutics (BCYC) United Kingdom $0.198B 0.00
Five Prime Therapeutics (FPRX) United States $0.193B 0.00
Arbutus Biopharma (ABUS) Canada $0.191B 0.00
Novavax (NVAX) United States $0.184B 0.00
EYEPOINT PHARMACEUTICALS, INC (EYPT) United States $0.184B 0.00
ARAVIVE, INC (ARAV) United States $0.184B 0.00
Fortress Biotech (FBIO) United States $0.183B 0.00
Pieris Pharmaceuticals (PIRS) United States $0.182B 0.00
Alcobra (ARCT) United States $0.180B 0.00
Windtree Therapeutics (WINT) United States $0.172B 0.00
TELA Bio (TELA) United States $0.170B 0.00
Spero Therapeutics (SPRO) United States $0.170B 0.00
PHASEBIO PHARMA (PHAS) United States $0.168B 0.00
Menlo Therapeutics (MNLO) United States $0.163B 0.00
Selecta Biosciences (SELB) United States $0.160B 0.00
Dyadic (DYAI) United States $0.159B 0.00
Aptinyx (APTX) United States $0.154B 0.00
Applied Genetic Technologies (AGTC) United States $0.149B 0.00
Strongbridge Biopharma (SBBP) United States $0.149B 3.97
Verastem (VSTM) United States $0.141B 0.00
Newron Pharmaceuticals SpA (NWPHF) Italy $0.134B 0.00
Northwest Biotherapeutics (NWBO) United States $0.130B 0.00
Abeona Therapeutics (ABEO) United States $0.130B 0.00
Arsanis (XFOR) United States $0.129B 0.00
VTv Therapeutics (VTVT) United States $0.128B 0.00
Clearside Biomedical (CLSD) United States $0.126B 0.00
Enzo Biochem (ENZ) United States $0.125B 0.00
Paratek Pharmaceuticals (PRTK) United States $0.121B 0.00
Liquidia Technologies (LQDA) United States $0.120B 0.00
Celyad SA (CYAD) Belgium $0.118B 0.00
Aduro Biotech (ADRO) United States $0.113B 0.00
Antibe Therapeutics (ATBPF) Canada $0.112B 0.00
Happiness Biotech Group (HAPP) China $0.110B 0.00
OvaScience (MLND) United States $0.106B 0.00
AVEO Pharmaceuticals (AVEO) United States $0.102B 0.00
SESEN BIO, INC (SESN) United States $0.102B 0.00
Proteostasis Therapeutics (PTI) United States $0.100B 0.00
Acorda Therapeutics (ACOR) United States $0.099B 0.00
Synlogic (SYBX) United States $0.096B 0.00
AIT Therapeutics (XAIR) United States $0.093B 0.00
Emmaus Life Sciences (EMMA) United States $0.090B 0.00
Catalyst Biosciences (CBIO) United States $0.089B 0.00
Orgenesis (ORGS) United States $0.087B 5.63
Adocia (ADOCY) France $0.086B 0.00
Prima BioMed (IMMP) Australia $0.084B 0.00
Catabasis Pharmaceuticals (CATB) United States $0.083B 0.00
Trevena (TRVN) United States $0.081B 0.00
NewLink Genetics (NLNK) United States $0.076B 0.00
Vaccinex (VCNX) United States $0.076B 0.00
ANIXA BIOSCIENCES INC (ANIX) United States $0.072B 0.00
Checkpoint Therapeutics (CKPT) United States $0.069B 0.00
Aridis Pharmaceuticals (ARDS) United States $0.066B 0.00
Pluristem Therapeutics (PSTI) Israel $0.064B 0.00
Idera Pharmaceuticals (IDRA) United States $0.062B 0.00
Sunesis Pharmaceuticals (SNSS) United States $0.062B 0.00
Organovo Holdings (ONVO) United States $0.060B 0.00
Curis (CRIS) United States $0.057B 0.00
DiaMedica Therapeutics (DMAC) United States $0.053B 0.00
Vascular Biogenics (VBLT) Israel $0.051B 0.00
AquaBounty Technologies (AQB) United States $0.049B 0.00
CollPlant Holdings (CLGN) Israel $0.044B 0.00
Evogene (EVGN) Israel $0.044B 0.00
Soligenix (SNGX) United States $0.043B 0.00
Celldex Therapeutics (CLDX) United States $0.040B 0.00
Celsion (CLSN) United States $0.037B 0.00
BioCardia (BCDA) United States $0.035B 0.00
Alimera Sciences (ALIM) United States $0.035B 0.00
Pulmatrix (PULM) United States $0.033B 0.00
Entera Bio (ENTX) Israel $0.033B 0.00
Bionano Genomics (BNGO) United States $0.032B 0.00
VistaGen Therapeutics (VTGN) United States $0.031B 0.00
Aptevo Therapeutics (APVO) United States $0.031B 0.00
Oncobiologics (OTLK) United States $0.029B 0.00
Unum Therapeutics (UMRX) United States $0.029B 0.00
VIVUS (VVUS) United States $0.029B 0.00
Novogen (KZIA) Australia $0.029B 0.00
Stellar Biotechnologies (EDSA) Canada $0.027B 0.00
Aerpio Pharmaceuticals (ARPO) United States $0.025B 0.00
AEterna Zentaris (AEZS) United States $0.022B 0.00
Signal Genetics (MGEN) United States $0.021B 0.00
Advaxis (ADXS) United States $0.021B 0.00
Titan Pharmaceuticals (TTNP) United States $0.019B 0.00
Genetic Technologies (GENE) Australia $0.017B 0.00
Aytu Bioscience (AYTU) United States $0.017B 0.00
TOCAGEN INC (TOCA) United States $0.014B 0.00
Cyclacel Pharmaceuticals (CYCC) United States $0.014B 0.00
Cesca Therapeutics (THMO) United States $0.013B 0.00
MYOS RENS Technology (MYOS) United States $0.013B 0.00
IMMURON (IMRN) Australia $0.013B 0.00
TRACON Pharmaceuticals (TCON) United States $0.012B 0.00
Cleveland BioLabs (CBLI) United States $0.012B 0.00
Prana Biotechnology (ATHE) Australia $0.011B 0.00
TrovaGene (TROV) United States $0.011B 0.00
Benitec Biopharma (BNTC) Australia $0.006B 0.00
Neuralstem (SNCA) United States $0.006B 0.00